Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype
Copyright © 2020 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: Familial Hypercholesterolemia (FH) is an autosomal dominant disease with an estimated prevalence between 1/200-250. It is under-treated and underdiagnosed. Massive data screening can increase the detection of patients with FH.
METHODS: Study population: Residents in the health coverage area (N: 195.000 inhabitants) and with at least one determination of cholesterol linked to low-density lipoproteins (LDL-C) carried out between January 1, 2010 and December 30, 2019. The highest LDL-C values were selected.
EXCLUSION CRITERIA: nephrotic syndrome, hypothyroidism, Hypothyroid treatment or triglycerides> 400 mg / dL. Seven algorithms suggestive of Familial Hypercholesterolemia Phenotype (HF-P) were analyzed, selecting the most efficient algorithm that could easily be translated into clinical practice.
RESULTS: Based on 6.264.877 assistances and 288.475 patients, after applying the inclusion-exclusion criteria, 504.316 tests were included, corresponding to 106.382 adults and 10.509 <18 years. The selected algorithm presented a prevalence of 0.62%. 840 patients with HF-P were detected, 55.8% being women and 178 <18 years old, 9.3% had a history of cardiovascular disease (CVD) and 16.4% had died. 65% of the patients in primary prevention had LDL-C values> 130 mg / dL and 83% in secondary prevention values> 70mg / dL. A ratio of 7.64 (1-18) patients with HF-P per analytical requesting physician was obtained.
CONCLUSIONS: Massive data screening and patient profiling are effective tools and easily applicable in clinical practice for the detection of patients with FH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis - 33(2021), 3 vom: 27. Mai, Seite 138-147 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
El rastreo masivo de datos es una segunda oportunidad para mejorar el manejo de los pacientes con fenotipo de hipercolesterolemia familiar |
|---|
| Beteiligte Personen: |
Zamora, Alberto [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.12.2021 Date Revised 14.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.arteri.2020.11.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321774299 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321774299 | ||
| 003 | DE-627 | ||
| 005 | 20231225180613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.arteri.2020.11.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1072.xml |
| 035 | |a (DE-627)NLM321774299 | ||
| 035 | |a (NLM)33618913 | ||
| 035 | |a (PII)S0214-9168(20)30112-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zamora, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype |
| 246 | 3 | 3 | |a El rastreo masivo de datos es una segunda oportunidad para mejorar el manejo de los pacientes con fenotipo de hipercolesterolemia familiar |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: Familial Hypercholesterolemia (FH) is an autosomal dominant disease with an estimated prevalence between 1/200-250. It is under-treated and underdiagnosed. Massive data screening can increase the detection of patients with FH | ||
| 520 | |a METHODS: Study population: Residents in the health coverage area (N: 195.000 inhabitants) and with at least one determination of cholesterol linked to low-density lipoproteins (LDL-C) carried out between January 1, 2010 and December 30, 2019. The highest LDL-C values were selected | ||
| 520 | |a EXCLUSION CRITERIA: nephrotic syndrome, hypothyroidism, Hypothyroid treatment or triglycerides> 400 mg / dL. Seven algorithms suggestive of Familial Hypercholesterolemia Phenotype (HF-P) were analyzed, selecting the most efficient algorithm that could easily be translated into clinical practice | ||
| 520 | |a RESULTS: Based on 6.264.877 assistances and 288.475 patients, after applying the inclusion-exclusion criteria, 504.316 tests were included, corresponding to 106.382 adults and 10.509 <18 years. The selected algorithm presented a prevalence of 0.62%. 840 patients with HF-P were detected, 55.8% being women and 178 <18 years old, 9.3% had a history of cardiovascular disease (CVD) and 16.4% had died. 65% of the patients in primary prevention had LDL-C values> 130 mg / dL and 83% in secondary prevention values> 70mg / dL. A ratio of 7.64 (1-18) patients with HF-P per analytical requesting physician was obtained | ||
| 520 | |a CONCLUSIONS: Massive data screening and patient profiling are effective tools and easily applicable in clinical practice for the detection of patients with FH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Familial Hypercholesterolemia | |
| 650 | 4 | |a Hipercolesterolemia Familiar | |
| 650 | 4 | |a Massive data screening | |
| 650 | 4 | |a Perfilado de pacientes | |
| 650 | 4 | |a Rastreo masivo de datos | |
| 650 | 4 | |a profiling of patients | |
| 650 | 7 | |a Cholesterol, LDL |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 700 | 1 | |a Paluzie, Guillem |e verfasserin |4 aut | |
| 700 | 1 | |a García-Vilches, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso Gisbert, Oriol |e verfasserin |4 aut | |
| 700 | 1 | |a Méndez Martínez, Ana Inés |e verfasserin |4 aut | |
| 700 | 1 | |a Plana, Núria |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Borjabad, Cèlia |e verfasserin |4 aut | |
| 700 | 1 | |a Ibarretxe, Daiana |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Urda, Anabel |e verfasserin |4 aut | |
| 700 | 1 | |a Masana, Luis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis |d 1996 |g 33(2021), 3 vom: 27. Mai, Seite 138-147 |w (DE-627)NLM091632536 |x 1578-1879 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2021 |g number:3 |g day:27 |g month:05 |g pages:138-147 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arteri.2020.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2021 |e 3 |b 27 |c 05 |h 138-147 | ||